Weight‑loss drugs lower key water‑conserving hormone

Glucagon‑like peptide‑1 receptor agonists, which mimic a natural digestive hormone, are used to treat diabetes and obesity by making patients feel full and stimulating insulin release. Doctors note that people on these drugs often lose water and sodium in their urine, and side effects such as nausea and diarrhea can lead to dehydration; patients are therefore advised to drink plenty of fluids. The body’s main water‑conserving hormone, arginine vasopressin, is produced by brain neurons, stored in the pituitary gland, and released when needed to tell the kidneys to reabsorb water instead of excreting it.

Human trial shows hormone drop

In a small human study of sixteen healthy adults, researchers gave a single dose of liraglutide and sampled blood and urine before and after the drug, after the participants drank a slightly salty drink. They found that the drug acutely lowered the level of arginine vasopressin in the blood and also reduced the secondary marker copeptin. The study also noted lower plasma potassium and higher urinary sodium, indicating that the medication dampens the hormone’s release and alters fluid balance.

Over a fourteen‑day experiment in rats, scientists injected liraglutide or saline and tracked food and water consumption. The drug initially reduced both intake, but by day fourteen the treated rats drank more water relative to food than controls, suggesting disrupted normal drinking patterns. Examination of pituitary tissue showed less stored vasopressin and protein‑tagging changes that impair hormone release, while kidney tissue displayed reduced expression and tagging of aquaporin channels that normally reabsorb water. Together the data show that liraglutide interferes with the brain‑kidney axis that regulates body fluid balance.